HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-Making

English version České info

Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infection, but biological efficacy alone is not enough to guide policy decisions about the role of ART in reducing HIV incidence. Epidemiology, economics, demography, statistics, biology, and mathematical modelling will be central in framing key decisions in the optimal use of ART. PLoS Medicine, with the HIV Modelling Consortium, has commissioned a set of articles that examine different aspects of HIV treatment as prevention with a forward-looking research agenda. Interlocking themes across these articles are discussed in this introduction. We hope that this article, and others in the collection, will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.

Vyšlo v časopise: HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-Making. PLoS Med 9(7): e32767. doi:10.1371/journal.pmed.1001259
Kategorie: Review
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001259

Souhrn

Zdroje

1. Joint United Nations Programme on HIV/AIDS 2011 World AIDS day report: how to get to zero: faster. smarter. better. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf. Accessed 25 November 2011

2. World Health Organization, United Nations Children's Fund, Joint United Nations Programme on HIV/AIDS 2011 Progress report 2011: global HIV/AIDS response. Epidemic update and health sector progress towards universal access Geneva World Health Organization

3. ShisanaORehleTSimbayiLZumaKJoosteS 2009 South African national prevalence, incidence, behaviour and communication survey, 2008. A turning tide among teenagers? Cape Town HSRC Press

4. SchwartlanderBStoverJHallettTAtunRAvilaC 2011 Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 377 2031 2041

5. US President's Emergency Plan for AIDS Relief 2011 August Guidance for the prevention of sexually transmitted hiv infections. Available: http://www.pepfar.gov/documents/organization/171303.pdf. Accessed 25 November 2011

6. Abdool KarimQAbdool KarimSSFrohlichJAGroblerACBaxterC 2010 Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329 1168 1174

7. GrantRMLamaJRAndersonPLMcMahanVLiuAY 2010 Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363 2587 2599

8. University of Washington International Clinical Research Center 2011 Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa. Available: http://depts.washington.edu/uwicrc/research/studies/files/PrEP_PressRelease-UW_13Jul2011.pdf. Accessed 25 May 2012

9. Rerks-NgarmSPitisuttithumPNitayaphanSKaewkungwalJChiuJ 2009 Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361 2209 2220

10. CelumCBaetenJM 2012 Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis 25 51 57

11. CohenMSChenYQMcCauleyMGambleTHosseinipourMC 2011 Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365 493 505

12. CohenJ 2011 HIV treatment as prevention. Science 334 1628

13. DonnellDBaetenJMKiarieJThomasKKStevensW 2010 Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375 2092 2098

14. AttiaSEggerMMullerMZwahlenMLowN 2009 Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23 1397 1404

15. EatonJWJohnsonLFSalomonJABärnighausenTBendavidE 2012 HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9 e1001245 doi:10.1371/journal.pmed.1001245

16. SmithMKPowersKAMuessigKEMillerWCCohenMS 2012 HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med 9 e1001260 doi:10.1371/journal.pmed.1001260

17. WilsonDP 2012 HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med 9 e1001231 doi:10.1371/journal.pmed.1001231

18. CohenMSDyeCFraserCMillerWCPowersKA 2012 HIV treatment as prevention: debate and commentary—will early infection compromise treatment-as-prevention strategies? PLoS Med 9 e1001232 doi:10.1371/journal.pmed.1001232

19. Meyer-RathGOverM 2012 HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions. PLoS Med 9 e1001247 doi:10.1371/journal.pmed.1001247

20. BärnighausenTSalomonJASangrujeeN 2012 HIV treatment as prevention: issues in economic evaluation. PLoS Med 9 e1001263 doi:10.1371/journal.pmed.1001263

21. DelvaWEatonJWMengFFraserCWhiteRG 2012 HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med 9 e1001258 doi:10.1371/journal.pmed.1001258

22. BoilyMCMâsseBAlsallaqRPadianNSEatonJW 2012 HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med 9 e1001250 doi:10.1371/journal.pmed.1001250

23. DelvaWWilsonDPAbu-RaddadLGorgensMWilsonD 2012 HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation. PLoS Med 9 e1001239 doi:10.1371/journal.pmed.1001239

24. GarnettGPAndersonRM 1993 Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Philos Trans R Soc Lond B Biol Sci 342 137 159

25. Eligibility for ART in Lower Income Countries (eART-linc) Collaboration 2008 Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 84 Suppl 1 i31 i36

26. LodiSPhillipsATouloumiGGeskusRMeyerL 2011 Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 cells/mm3: assessment of need following changes in treatment guidelines. Clin Infect Dis 53 817 825

27. GranichRMGilksCFDyeCDe CockKMWilliamsBG 2009 Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373 48 57

28. SweatMMorinSCelentanoDMulawaMSinghB 2011 Community-based intervention to increase HIV testing and case detection in people aged 16–32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis 11 525 532

29. RosenSFoxMP 2011 Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 8 e1001056 doi:10.1371/journal.pmed.1001056

30. KatzITEssienTMarindaETGrayGEBangsbergDR 2011 Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS 25 2177 2181

31. Schöni-AffolterFKeiserOMwangoAStringerJLedergerberB 2011 Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. PLoS ONE 6 e27919 doi:10.1371/journal.pone.0027919

32. CornellMGrimsrudAFairallLFoxMPvan CutsemG 2010 Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007. AIDS 24 2263 2270

33. BrinkhofMWDabisFMyerLBangsbergDRBoulleA 2008 Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86 559 567

34. EstillJAubriereCEggerMJohnsonLWoodR 2012 Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis. AIDS E-pub ahead of print. doi:10.1097/QAD.0b013e3283536988

35. PhillipsANPillayDMinersAHBennettDEGilksCF 2008 Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 371 1443 1451 doi:10.1016/S0140-6736(08)60624-8

36. WalenskyRPWoodRCiaranelloALPaltielADLorenzanaSB 2010 Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: a model-based analysis. PLoS Med 7 e1000382 doi:10.1371/journal.pmed.1000382

37. PhillipsANPillayDGarnettGBennettDVitoriaM 2011 Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second line antiretroviral regimens in resource-limited settings. AIDS 25 843 850

38. MontanerJSLimaVDBarriosRYipBWoodE 2010 Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 376 532 539

39. HollingsworthTDAndersonRMFraserC 2008 HIV-1 transmission, by stage of infection. J Infect Dis 198 687 693

40. PowersKAGhaniACMillerWCHoffmanIFPettiforAE 2011 The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 378 256 268

41. Kaiser Family Foundation 2011 International AIDS assistance from donor governments: commitments & disbursements, 2002–2010. Available: http://facts.kff.org/chart.aspx?ch=946. Accessed 25 November 2011

42. MenziesNABerrutiAABerzonRFillerSFerrisR 2011 The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 25 1753 1760

43. NjeuhmeliEForsytheSReedJOpuniMBollingerL 2011 Voluntary medical male circumcision: modeling the impact and cost of expanding male circumcision for HIV prevention in eastern and southern Africa. PLoS Med 8 e1001132 doi:10.1371/journal.pmed.1001132

44. SweatMGregorichSSangiwaGFurlongeCBalmerD 2000 Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet 356 113 121

45. AllenSSerufiliraABogaertsJVan de PerrePNsengumuremyiF 1992 Confidential HIV testing and condom promotion in Africa. Impact on HIV and gonorrhea rates. JAMA 268 3338 3343

46. NuwahaFTumwesigyeEKasasaSAsiimweSWanaG 2009 Population-level changes in knowledge of HIV status, stigma and HIV risk behaviors after district-wide door to door voluntary counseling and testing (VCT) in Bushenyi District, Uganda [abstract]. 16th Conference on Retroviruses an Opportunisitic Infections; 8–11 February 2009; Montreal, Canada

47. The aids2031 Consortium 2011 AIDS: taking a long-term view. Upper Saddle River (Jew Jersey): FT Press Science

48. ReschSKorenrompEStoverJBlakleyMKrubinerC 2011 Economic returns to investment in AIDS treatment in low and middle income countries. PLoS ONE 6 e25310 doi:10.1371/journal.pone.0025310

49. Tan-Torres EdejerTBaltussenRAdamTHutubessyRAcharyaA 2004 Making choices in health: WHO guide to cost-effectiveness analysis Geneva World Health Organization

50. BrandeauMLZaricGSRichterA 2003 Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis. J Health Econ 22 575 598 doi:10.1016/S0167-6296(03)00043-2

51. CohenMSMuessigKESmithMKPowersKKashubaAD 2012 Antiviral agents and HIV prevention: controversies, conflicts and consensus. AIDS 12 E-pub ahead of print. doi:10.1097/QAD.0b013e3283543e83

52. GranichRGuptaSSutharABSmythCHoosD 2011 Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 9 446 469

53. Abu-RaddadLJLonginiIMJr 2008 No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS 22 1055 1061

54. EatonJWHallettTBGarnettGP 2011 Concurrent sexual partnerships and primary HIV infection: a critical interaction. AIDS Behav 15 687 692

55. GoodreauSMCasselsSKasprzykDMontanoDEGreekA 2012 Concurrent partnerships, acute infection and HIV epidemic dynamics among young adults in Zimbabwe. AIDS Behav 16 312 322

56. ToddJGlynnJRMarstonMLutaloTBiraroS 2007 Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. AIDS 21 Suppl 6 S55 S63

57. ReynoldsSJMakumbiFNakigoziGKagaayiJGrayRH 2011 HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 25 473 477 doi:10.1097/QAD.0b013e3283437c2b

58. World Health Organization 2010 Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision Geneva World Health Organization

59. World Health Organization 2012 April Guidance on couples HIV testing and counseling including antiretroviral therapy for treatment and prevention in serodiscordant couples Geneva World Health Organization

60. World Health Organization 2011 WHO consultation on the strategic use of antiretrovirals for treatment and prevention of HIV Geneva World Health Organization